Leukotriene Receptor Antagonists: Clinical Effects

Holloway L , Beasley R , Roche WR . The pathology of fatal asthma. In: Busse WW , Holgate ST , eds. Asthma and Rhinitis. Boston: Blackwell, 1995: 109–172.

Djukanovic R. Bronchial biopsies. In: Busse WW , Holgate ST , eds. Asthma and Rhinitis. Boston: Blackwell, 1995: 118–29.

Piper PJ . Leukotrienes and the airways. Eur J Anaesthesiol 1989; 6: 241–55.

Barnes NC , Kuitert LM . Influence of leukotriene antagonists on baseline pulmonary function and asthmatic responses. Adv Prostaglandin, Thromboxane Leukotriene Res 1994; 22: 217–26.

Drazen JM , Lilly CM , Sperling R , Rubin P , Israel E. Role of cysteinyl leukotrienes in spontaneous asthmatic responses. Adv Prostaglandin Thromboxane Leukotriene Res 1994; 22: 251–62.

British Thoracic Society. Guidelines for management of asthma in adults I-Chronic persistent asthma. BMJ 1990; 301: 651–3.

International consensus report on the diagnosis and management of asthma. Clin Exp Allergy 1992; 22(Suppl): 1–72.

Feldberg W , Kellaway CH . Liberation of histamine and formation of lysocrithin like substances by cobra venom. J Physiol 1938; 94: 187–226.

Brocklehurst WE . The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol 1960; 151: 416–35.

Murphy RC , Hammarstrom S , Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Nat Acad Sci USA 1979; 76: 4275–9.

Kaiser E , Chiba P , Zaky K. Phospholipases in biology and medicine. Clin Biochem 1990; 23: 347–70.

Dixon RA , Diehl RE , Opas E Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343: 282–4.

Hatzelmann A , Goossens J , Fruchtmann R , Mohrs K , Raddatz S , Müller-Peddinghauss R. Inversely correlated inhibition of human 5-lipoxygenase activity by BAYX1005 and other quinoline derivatives in intact cells and a cell-free system—implications for the function of 5-lipoxygenase activating protein. Biochem Pharmacol 1994; 47: 2259–68.

Orning L , Kaijser L , Hammarstrom S. In vivo metabolism of leukotriene C4 in man: urinary excretion of leukotriene E4. Biochem Biophy Res Commun 1985; 130: 214–20.

Owen W.F. Jr. , Soberman RJ , Yoshimoto T , Sheffer AL , Lewis RA , Austen KF . Synthesis and release of leukotriene C₄ by human eosinophils. J Immunol 1987; 138: 532–8.

Fox CC , Kagey-Sobotka A , Schleimer RP , Peters SP , MacGlashan DW , Lichtenstein LM . Mediator release from human basophils and mast cells from lung and intestinal mucosa. Int Arch Allergy Appl Immunol 1985; 77: 130–6.

Schleimer RP , Schulman ES , MacGlashan D.W. Jr. Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest 1983; 71: 1830–5.

Calhoun WJ , Jarjour NN . Macrophages and macrophage diversity in asthma. In: Busse WW , Holgate ST , eds. Asthma and Rhinitis. Boston: Blackwell, 1995: 467–73.

Dahlen SE , Dahlen B , Kumlin M , Bjarck T , Ihre E , Zetterstrom O. Clinical and experimental studies of leukotrienes as mediators of airway obstruction in humans. Adv Prostaglandin Thromboxane Leukotriene Res 1994; 22: 155–66.

Ford-Hutchinson AW , Bray MA , Doig MV Leukotriene B4 a potent chemokinetic and aggregating substance released from PMN leukocytes. Nature 1980; 286: 264–5.

Evans DJ , Barnes PJ , Spaethe SM , Van Alstyne EL , Mitchell MI , O'Connor BJ . The effect of a leukotriene B₄ receptor antagonist, LY2933111, on allergen-induced responses in asthma. Thorax (in press).

Gardiner PJ , Abram TS , Tudhope SR , Cuthbert NJ , Norman P , Brink C. Leukotriene receptors and their selective antagonists. Adv Prostaglandin Thromboxane Leukotriene Res 1994; 22: 49–61.

Evans DJ , Coulby L , Spaethe S Leukotriene B₄ antagonist LY 293,111 inhibits neutrophil recruitment to the airway and modulates inflammatory response following allergen challenge [Abstract]. Eur Res J 1995; 8(Suppl. 19): 289S.

Barnes NC , Piper PJ , Costello JF . Comparative effects of inhaled leukotriene C4, leukotriene D4 and histamine in normal human subjects. Thorax 1984; 39: 500–4.

Griffin M , Weiss JW , Leitch AG Effects of leukotriene D on the airways in asthma. N Engl J Med 1983; 308: 436–9.

Davidson AB , Lee TH , Scanion PD Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic individuals. Am Rev Resp Dis 1987; 135: 333–7.

Marom Z , Shekhamer JH , Bach MK , Morton DR , Kaliner M. Slow-reacting substances leukotrienes C4 and D4 increase the release of mucus from human airways in vitro. Am Rev Resp Dis 1982; 126: 449–51.

Peck MJ , Piper PJ , Williams TJ . The effect of leukotrienes C4 and D4 on the microvasculation of guinea pig skin. Prostaglandins 1981; 21: 315–21.

Arm JP , Spur BW , Lee TH . The effects of inhaled leukotriene E4 on the airways responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988; 82: 654–60.

Bel EH , Van der Veen H , Kramps JA , Dijkman JH , Strek PJ . Maximal airways narrowing to inhaled leukotriene D4 in normal subjects. Am Rev Resp Dis 1987; 136: 979–84.

Barnes NC , Piper PJ , Costello JF . Actions of inhaled leukotrienes and their interaction with other allergic mediators in human volunteers. Prostaglandins 1984; 28: 629–31.

Laitenen LA , Laitenen A , Haahtela T Leukotriene E₄ and granulocytic infiltration into asthmatic airways. Lancet 1993; 341: 989–90.

Underwood DC , Osborn RR , Rochnowicz S , Newholme SJ , Torphy TJ , Hay DWP . Pranlukast, a potent and selective cysteinyl leukotriene (CysLT) receptor antagonist attenuates pro-inflammatory responses induced by leukotriene (LT) D₄. Eur Resp J 1995; 8(Suppl. 19): 288S.

Wenzel SE , Larsen GL , Johnston LK , Voelkel NF , Westcott JY . Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Resp Dis 1990; 142: 112–1935.

Taylor G , Black P , Turner N Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; 1: 584–8.

Wardlaw AJ , Hay H , Cromwell O , Collins JV , Kay AB . Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 1989; 84: 19–26.

Okubo T , Takahashi H , Sumitomo M , Shindoh K , Suzuki S. Plasma levels of leukotrienes C4 and D4 during wheezing attack in asthmatic patients. Int Arch Allergy Appl Immunol 1987; 84: 149–55.

Barnes N , Piper PJ , Costello J. The effect of an oral leukotriene antagonist L-649, 923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. J Allergy Clin Immunol 1987; 79: 816–21.

Evans JM , Barnes NC , Zakrzweski JT L-648,051, a novel cysteinyl leukotriene antagonist is active by the inhaled route in man. Br J Clin Pharmacol 1989; 28: 125–35.

Phillips GD , Rafferty P , Robinson C , Holgate ST . Dose-related antagonism of leukotriene D4-induced bronchoconstriction by p.o. administration of LY-171883 in nonasthmatic subjects. J Pharmacol Expl Ther 1988; 246: 732–8.

Smith LJ , Geller J , Elbright L , Glass M , Thynum PT . Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am Rev Resp Dis 1990; 141: 988–92.

Kips JC , Joos GF , De Lepelaire I MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human. Am Rev Resp Dis 1991; 144: 617–21.

Wahedna I , Wisniewski AS , Tattersfield AE . Effect of RG 12525 an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma. Br J Clin Pharmacol 1991; 32: 512.

Fujimara M , Sakahoto S , Kamis Y , Matsuda T. Effect of a leukotriene antagonist ONO-1078 on bronchial hyperresponsiveness in patients with asthma. Resp Med 1993; 87: 133–8.

O'Shaughnessy TC , Georgiou P , Howland K , Barnes NC . The effect of pranlukast, an oral leukotriene antagonist, on leukotriene D4 (LTD₄) challenge in normal male subjects. Thorax (in press).

Evans JM , Piper PJ , Costello JF . The pharmacological profile of SKF104,353-Z₂, a potent, selective, inhaled leukotriene antagonist of cysteinyl leukotrienes in normal man. Adv Prostaglandin Thromboxane Leukotriene Res 1991; 21: 469–72.

Israel E , Dermakarian R , Rosenberg M The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323: 1740–4.

O'Byrne PM , Watson RM , Strong HA , Wyile G. The effect of treatment with a 5-lipoxygenase inhibitor BAY × 1005 on allergen-induced asthmatic responses in human subjects. Am Rev Resp Crit Care Med 1994; 149: A532.

Friedman BS , Bel EW , Bunfinx A Oral leukoriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Resp Dis 1993; 147: 839–44.

Zakrzewski JT , Barnes NC , Costello JF , Piper PJ . Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Resp Dis 1987; 136: 779–82.

Taylor IK , O'Shaughnessy KM , Fuller RW , Dollery CT . Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen induced bronchoconstriction and airways hyperreactivity in atopic subjects. Lancet 1991; 337: 690–4.

Rasmussen JB , Margolskee DJ , Eriksson LO , Williams VC , Andersson KE . Leukotriene (LT) D4 is involved in antigen-induced asthma: a study with the LTD4 receptor antagonist MK-571. An N Y Acad Sci 1991; 629: 436.

Aalbers R , De Monchy J. Cysteinyl leukotriene receptor antagonist, effect on allergic bronchoconstriction and airway hyperreactivity. Lancet 1991; 338: 445.

Manning PJ , Watson RM , Margolskee DJ Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4 receptor antagonist. N Engl J Med 1990; 323: 1736–9.

Finnerty JP , Wood-Baker R , Thomson H , Holgate ST . Role of leukotrienes in exercise-induced asthma. Am Rev Resp Dis 1992; 145: 746–9.

Hui KP , Barnes NC . Lung function improvement in asthma with a cysteinyl leukotriene receptor antagonist. Lancet 1991; 337: 1062–3.

Gaddy JN , Margolskee DJ , Bush RE , Williams VC , Busse WW . Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Resp Dis 1992; 146: 358–63.

Israel E , Rubin P , Kemp JP The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993; 119: 1059–66.

Christie PE , Tagari P , Ford-Hutchinson AW Urinary leukotriene E4 concentrations after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Resp Dis 1991; 143: 1025–59.

Dahlen B , Margolskee DJ , Zetterstrom O , Dahlen SE . Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin-sensitive asthmatic subjects. Thorax 1993; 48: 1205–10.

Dahlen B , Kumlin M , Margolskee DJ The leukotriene receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine aspirin in aspirin-sensitive asthmatics. Eur Resp J 1993; 6: 1018–26.

Cloud ML , Enas GC , Kemp J A specific LTD4/LTE4 receptor antagonist improves pulmonary function in patients with mild chronic asthma. Am Rev Resp Dis 1989; 140: 336–9.

Spector SL , Smith LJ , Glass M and the Accolate^™ Asthma Trialists Group. Effects of 6 weeks of therapy with oral doses of ICI 204, 219, a leukotriene D₄ receptor antagonist, in subjects with bronchial asthma. Am Rev Resp Dis 1994; 150: 618–23.